Quantum BioPharma Clarifies Share Consolidation Terms Ahead of Shareholder Meeting

Quantum BioPharma files a supplement to clarify share consolidation terms, including fractional share rounding and a 70% voting power cap, ahead of its November 10 shareholder meeting.

Chicago Metrowire Staff
••Healthcare
Quantum BioPharma Clarifies Share Consolidation Terms Ahead of Shareholder Meeting

Quantum BioPharma (NASDAQ: QNTM) has filed a supplement to its September 28, 2026, management information circular, correcting and restating the proposed special resolution that would authorize a consolidation of its Class A multiple voting shares and Class B subordinate voting shares. The supplement comes ahead of the company’s annual general and special meeting of shareholders scheduled for November 10, 2026. The clarification is important because it provides shareholders with precise terms on how fractional shares will be treated and how voting power will be capped, which could influence the outcome of the vote and the company’s capital structure.

Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. The company also clarified that it will implement measures to cap the aggregate voting power of multiple voting shareholders at 70% if cancellations of Class B subordinate voting shares would otherwise cause that threshold to be exceeded. These details are critical for investors assessing the potential dilution and control implications of the consolidation.

Previously submitted proxies will remain valid unless revoked or changed, and shareholders are encouraged to review the supplemental materials before the meeting. The full press release can be accessed at https://ibn.fm/aqzMe. For ongoing updates on Quantum BioPharma, the company’s newsroom is available at https://ibn.fm/QNTM.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights.

The announcement was distributed by MissionIR, a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is part of the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit MissionIR.

Blockchain Registration

QR Code for Blockchain Registration